Technology
Health
Pharmaceutical

PhaseBio

$6.23
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (0.48%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell PhaseBio and other stocks, options, ETFs, and crypto commission-free!

About

PhaseBio Pharmaceuticals, Inc. engages in the development and commercialization of biotherapeutics for the treatment of orphan diseases. It focuses on cardiopulmonary disorders. Read More The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.

Employees
19
Headquarters
Malvern, Pennsylvania
Founded
2002
Market Cap
148.30M
Price-Earnings Ratio
Dividend Yield
Average Volume
135.65K
High Today
$6.29
Low Today
$5.75
Open Price
$6.10
Volume
93.43K
52 Week High
$8.88
52 Week Low
$2.55

Collections

Technology
Health
Pharmaceutical
2018 IPO
US
North America

News

Guru FocusMar 6

PhaseBio to Present at Cowen and Company 39th Annual Health Care Conference

MALVERN, Pa. and SAN DIEGO, March 06, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. ( PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the Cowen and Company 39th Annual Health Care Conference on Wednesday, March 13, at 10:40 a.m. EDT in Boston. A live and archived version of the presentation will be available on...

337

Earnings

-$10.45
-$7.07
-$3.69
-$0.31
Q3 2018
Q4 2018
Estimated
-$0.31 per share
Actual
Available Mar 26, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.